Study finds CDK4/6 plus EGFR blockade kills pancreatic cancer cells without KRAS drugs
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
0








